We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for IDEXX Laboratories' (IDXX) Q3 Earnings?
Read MoreHide Full Article
IDEXX Laboratories, Inc. (IDXX - Free Report) is slated to report third-quarter 2019 results on Oct 31, before market open. In the last reported quarter, the company delivered a positive earnings surprise of 4.38%. IDEXX’s earnings beat the Zacks Consensus Estimate in the last four quarters, the average positive surprise being 8.23%.
Let's take a look at how things are shaping up prior to this announcement.
Key Catalysts
IDEXX's strong earnings trajectory is expected to have continued through the third quarter, courtesy of a global surge in Companion Animal Group (CAG) Diagnostics revenues.
Of late, the company has been registering solid organic revenues in this segment on gains from consumable and reference lab as well as the growing acceptance of Rapid Assays, and Veterinary Software, Services and Diagnostic Imaging Systems.
In the United States, IDEXX has been generating strong CAG Diagnostic recurring revenues, led by steady growth in reference lab, consumables and rapid assay sales. Growth in the Veterinary Software portfolio can be attributed to strength in the global catalyst install base of Cornerstone, Neo and Animana systems. These trends are expected to have continued in the to-be-reported quarter.
International reference laboratory services are likely to have seen a robust third quarter, courtesy of the company’s efforts to advance commercial measures while maintaining momentum in international markets’ catalyst install bases.
The Zacks Consensus Estimate of $527 million for CAG Diagnostics revenues suggests a 10.3% improvement from the year-ago quarter’s reported figure.
The company expects organic growth of 11-12% for 2019 CAG Diagnostic recurring revenues. We assume that this segment has started contributing to the company’s top line from the third quarter.
Other Factors
Additionally, the Water Business, of late, is gaining traction from encouraging test results in the United States and the global go-direct initiatives. The business witnessed 10% organic growth in the last reported quarter, driven by mid-single-digit growth in the United States, and considerable growth in Asia and Latin America. This trend most likely continued in the third quarter.
The consensus mark for Water business revenues stands at $35.6 million for the to-be-reported quarter, implying a 7.6% increase from the year-earlier reported number.
Strong organic revenue growth in the Livestock, Poultry and Dairy (LPD) segment is likely to show on the company’s third-quarter results, led by gains in herd health screening, poultry and pregnancy products sales.
On the flip side, increased pressure on China LPD revenues in the last reported quarter, due to the African swine fever outbreak and Brexit, is likely to have adversely impacted the company’s top line during the to-be-reported quarter.
The Zacks Consensus Estimate for third-quarter 2019 revenues is pegged at $597.4 million, indicating a 9.5% rise from the prior-year quarter’s reported figure.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for IDEXX this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But this is not the case here as you will see below.
Earnings ESP: IDEXX has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The stock carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering from the same space with the right combination to surpass expectations this earnings season.
Vertex Pharmaceuticals (VRTX - Free Report) has an Earnings ESP of +2.24% and a Zacks Rank #1.
DENTSPLY SIRONA (XRAY - Free Report) has an Earnings ESP of +5.05% and a Zacks Rank of 3.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.50% per year. So be sure to give these hand-picked 7 your immediate attention.
Image: Bigstock
What's in Store for IDEXX Laboratories' (IDXX) Q3 Earnings?
IDEXX Laboratories, Inc. (IDXX - Free Report) is slated to report third-quarter 2019 results on Oct 31, before market open. In the last reported quarter, the company delivered a positive earnings surprise of 4.38%. IDEXX’s earnings beat the Zacks Consensus Estimate in the last four quarters, the average positive surprise being 8.23%.
Let's take a look at how things are shaping up prior to this announcement.
Key Catalysts
IDEXX's strong earnings trajectory is expected to have continued through the third quarter, courtesy of a global surge in Companion Animal Group (CAG) Diagnostics revenues.
Of late, the company has been registering solid organic revenues in this segment on gains from consumable and reference lab as well as the growing acceptance of Rapid Assays, and Veterinary Software, Services and Diagnostic Imaging Systems.
In the United States, IDEXX has been generating strong CAG Diagnostic recurring revenues, led by steady growth in reference lab, consumables and rapid assay sales. Growth in the Veterinary Software portfolio can be attributed to strength in the global catalyst install base of Cornerstone, Neo and Animana systems. These trends are expected to have continued in the to-be-reported quarter.
IDEXX Laboratories, Inc. Price and EPS Surprise
IDEXX Laboratories, Inc. price-eps-surprise | IDEXX Laboratories, Inc. Quote
International reference laboratory services are likely to have seen a robust third quarter, courtesy of the company’s efforts to advance commercial measures while maintaining momentum in international markets’ catalyst install bases.
The Zacks Consensus Estimate of $527 million for CAG Diagnostics revenues suggests a 10.3% improvement from the year-ago quarter’s reported figure.
The company expects organic growth of 11-12% for 2019 CAG Diagnostic recurring revenues. We assume that this segment has started contributing to the company’s top line from the third quarter.
Other Factors
Additionally, the Water Business, of late, is gaining traction from encouraging test results in the United States and the global go-direct initiatives. The business witnessed 10% organic growth in the last reported quarter, driven by mid-single-digit growth in the United States, and considerable growth in Asia and Latin America. This trend most likely continued in the third quarter.
The consensus mark for Water business revenues stands at $35.6 million for the to-be-reported quarter, implying a 7.6% increase from the year-earlier reported number.
Strong organic revenue growth in the Livestock, Poultry and Dairy (LPD) segment is likely to show on the company’s third-quarter results, led by gains in herd health screening, poultry and pregnancy products sales.
On the flip side, increased pressure on China LPD revenues in the last reported quarter, due to the African swine fever outbreak and Brexit, is likely to have adversely impacted the company’s top line during the to-be-reported quarter.
The Zacks Consensus Estimate for third-quarter 2019 revenues is pegged at $597.4 million, indicating a 9.5% rise from the prior-year quarter’s reported figure.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for IDEXX this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But this is not the case here as you will see below.
Earnings ESP: IDEXX has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The stock carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering from the same space with the right combination to surpass expectations this earnings season.
Alexion Pharmaceuticals, Inc has an Earnings ESP of +1.22% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Vertex Pharmaceuticals (VRTX - Free Report) has an Earnings ESP of +2.24% and a Zacks Rank #1.
DENTSPLY SIRONA (XRAY - Free Report) has an Earnings ESP of +5.05% and a Zacks Rank of 3.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.50% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>